Henry Schein (HSIC) delivered earnings and revenue surprises of 5.17% and 2.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

The global periodontal disease treatment market is projected to reach USD 3.63 billion by 2030 from USD 2.58 billion in 2024, growing at a CAGR of 5.9% during the forecast period 2024-2030. In all the ...

Henry Schein Inc. is a healthcare solutions company that provides products and services to medical and dental professionals ... in this litigation, please contact Tashia Poore either by email ...

Activist investor Ananym Capital Management is urging healthcare products distributor Henry Schein to refresh its board, cut costs, tackle succession planning and consider selling its medical ...

Henry Schein (HSIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael ...

Gulf International Bank UK Ltd trimmed its position in Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 3.1% in the 3rd ...

Yes. So if you look at the medical market for Henry Schein, you put aside the ups and downs of the flu season, whether it's vaccines, COVID, and general flu vaccine, those may shift up or down ...

Henry Schein posts Q3 adjusted EPS of $1.23, topping forecasts, while sales of $3.17 billion fall short. The company revises ...

Analysts' ratings for Henry Schein (NASDAQ:HSIC ... products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates ...

The health care products maker posted revenue of $3.17 billion in the period, which missed Street forecasts. Nine analysts surveyed by Zacks expected $3.24 billion. Henry Schein expects full-year ...

The dental supplies firm raised the lower end of its 2024 adjusted earnings projection, and now anticipates a range between $4.74 and $4.82 a share, compared with the prior $4.70-to-$4.82 a share ...